期刊文献+

鲍曼不动杆菌分布特征及耐药趋势的临床研究 被引量:20

The clinical research of clinical distribution and drug resistance of Acinetobacter baumanii
下载PDF
导出
摘要 目的了解鲍曼不动杆菌的临床分布及其对常用抗生素的耐药状况,为临床使用抗生素治疗提供依据。方法采用回顾性方法,统计分析273株鲍曼不动杆菌的标本来源、感染科室分布及耐药状况。结果273株鲍曼不动杆菌中,252株来自痰及支气管吸出物(占92.3%),其次为伤口分泌物12株(占4.4%)。鲍曼不动杆菌的感染科室ICU病房检出率最高,占40.7%,其次为呼吸内科,占16.1%。273株鲍曼不动杆菌中,48株鲍曼不动杆菌呈多重耐药菌株,对头孢哌酮/舒巴坦耐药率最低(10.0%),氨苄青霉素(97.0%)耐药率最高。慢性肺部疾病和脑血管疾患是鲍曼不动杆菌感染病例的主要基础疾病。结论鲍曼不动杆菌临床分离株多来自于痰及支气管吸出物标本,感染率最高为ICU病房,并对多种抗菌药物的耐药率较高,临床应加强对鲍曼不动杆菌耐药性的监控并防治耐药菌株的传播流行。 Objective To investigate the clinical distribution and the drug resistance of Acinetobacter baumanii in order to offer reference for the clinical antibiotic therapeutics.Methods The strains of Acinetobacter baumanii were retrospective statistical analyzed about collection source,clinical distribution and the result of sensitivity to antibiotics.Results Among 273 isolates,252 (92.3%) came from sputum and bronchial aspiration material,12 (4.4%) from tresis vulnus excreta.The most strains from intensive care unit,accounting for 40.7%.16.1% from respiratory department.48 strains of Acinetobacter baumanii were multidrug resistant.The lowest rate of drug-resistance was cefoperazone-sulperazon (10.0%).The highest rate of drug-resistance was ampicillin (97.0%).The chronicity pulmonary disease and cerebral vessels disease which were infected Acinetobacter baumanii.Conclusion Clinical isolates of Acinetobacter baumannil came from the sputum,bronchial aspiration material and intensive care unit mainly and their resistant rates were rather high.More attention should be paid to the surveillance of antimicrobial resistance of Acinetobacter baumannii in clinics and prevent transmission and epidemic of their resistance strains in order to infection effectually and delaying the occurrence of bacteria resistance.
出处 《中国现代医药杂志》 2010年第2期33-36,共4页 Modern Medicine Journal of China
关键词 鲍曼不动杆菌 临床分布 耐药 Acinetobacter baumanii Clinical distribution Drug resistance
  • 相关文献

参考文献10

  • 1乔宁,喻华,刘新.284株鲍曼不动杆菌的感染及耐药性分析[J].西部医学,2005,17(3):271-272. 被引量:13
  • 2项勤,朱国飞,李婷婷.鲍曼不动杆菌的分布特点及耐药性分析[J].中国预防医学杂志,2008,9(3):226-227. 被引量:26
  • 3莫瑞琴,朱剑峰,汤丽霞.138株鲍曼不动杆菌的临床分布及耐药性分析[J].右江民族医学院学报,2009,31(1):84-85. 被引量:11
  • 4Daher JA, Shaar TJ, Lababidi HM. Microorgnisms profile and antimicrobial susceptibility in the intensive care unit: the emergence of a resistant pathogen acinetobacter baumanil. Chest Meeting Abstracts, 2006,130:217. 被引量:1
  • 5李家泰,李耘,齐慧敏,代表中国细菌耐药监测研究组.2002—2003年中国革兰阴性细菌耐药性监测研究[J].中华检验医学杂志,2005,28(1):19-29. 被引量:296
  • 6Naas T, Levy M, Hirschauer C, et al. Outbreak of Carbapenem- Resistant Acinetobacter baumannii Producing the Carbapenemase OXA-23 in a Tertiary Care Hospital of Papeete, French Polynesia. J Clin Microbiol,2005,43(9): 4826-4829. 被引量:1
  • 7Paterson DL, Bonomo RA. Extended-Spectrum β-Lactamases: a Clinical Update. Clin Microbiol Rev,2005,18(4): 657-686. 被引量:1
  • 8Luzzaro F, Mezzatesta M, Mugnaioli C, et al. Trends in Production of Extended-Spectrum β-Lactamases among Enterobacteria of Medical Interest: Report of the Second Italian Nationwide Survey. J Clin Microbiol,2006,44(5):1659-1664. 被引量:1
  • 9Crossman LC, Gould VC, Dow JM, et al. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol,2008,9(4): R74. 被引量:1
  • 10Mastoraki A, Douka E, Kriaras I, et al. Preventing strategy of multidrug-resistant Acinetobacter baumanii susceptible only to colistin in cardiac surgical intensive care units. J Cardiothorac Surg, 2008,33:1086-1090. 被引量:1

二级参考文献16

  • 1吴宗宝,丁式行,李爱娟.鲍氏不动杆菌致呼吸机相关性肺炎54例分析[J].中华医院感染学杂志,2004,14(11):1302-1304. 被引量:14
  • 2王金良.密切注视鲍曼不动杆菌的耐药发展趋势[J].中华检验医学杂志,2005,28(4):355-356. 被引量:194
  • 3黄志华,陈守涛,陈丹,林其昌,陈公平,金咏絮.214例鲍氏不动杆菌的感染分布及耐药性[J].中华医院感染学杂志,2006,16(6):700-701. 被引量:30
  • 4中华人民共和国卫生部医政司.全国临床检验操作规程[M].南京:东南大学出版社,2002. 被引量:2
  • 5Cisneros JM, Reyes MJ, Pachon J, et al. Bacteremia due to Acinerobacer baumannii: epidemiology, clinical findings, and prognostic features [J]. Clin Infect Dis, 1996,22 (6) : 1026 - 1032. 被引量:1
  • 6National Committee for Clinical Laboratory Standard, 2002. Performance Standards for Antimicrobial Susceptibility Testing. NCCLS, Wayne, Pa. 被引量:1
  • 7Rhomberg PR, Jones RN , MYSTIC Study Group. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials:report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis, 2003,47:365-372. 被引量:1
  • 8Pfaller MA, Jones RN , MYSTIC Study Group. Antimicrobial susceptibility of inducible Amp C β-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. Int J Antimicrob Agents, 2002,19:383-388. 被引量:1
  • 9Sader HS, Biedenbach DJ ,Jones RN. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48440 Enterobacteriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis, 2003,47:361-364. 被引量:1
  • 10Sader HS, Gales AC, Pfaller MA, et al. Pathogen frequency and resistance patterns in Brazilian hospitals:summary of results from three years of the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis, 2001,5:200-214. 被引量:1

共引文献340

同被引文献154

引证文献20

二级引证文献97

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部